Trials / Recruiting
RecruitingNCT07223047
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 252 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
Conditions
- Advanced Solid Malignancies
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986523 | Specified dose on specified days |
| DRUG | Gemcitabine | Specified dose on specified days |
| DRUG | Nab-Paclitaxel | Specified dose on specified days |
| DRUG | Cetuximab | Specified dose on specified days |
| DRUG | Pembrolizumab | Specified dose on specified days |
Timeline
- Start date
- 2025-11-25
- Primary completion
- 2028-10-13
- Completion
- 2028-10-13
- First posted
- 2025-10-31
- Last updated
- 2026-04-13
Locations
8 sites across 3 countries: United States, Canada, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07223047. Inclusion in this directory is not an endorsement.